Triple-negative breast cancer: clinical features and patterns of recurrence
R Dent, M Trudeau, KI Pritchard, WM Hanna… - Clinical cancer …, 2007 - AACR
Purpose: To compare the clinical features, natural history, and outcomes for women with “triple-negative”
breast cancer with women with other types of breast cancer. Experimental …
breast cancer with women with other types of breast cancer. Experimental …
[PDF][PDF] Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study
…, M Ennis, KI Pritchard, ME Trudeau… - Journal of clinical …, 2002 - academia.edu
Purpose: Insulin, a member of a family of growth factors that includes insulin-like growth factor
(IGF)-I and IGF-II, exerts mitogenic effects on normal and malignant breast epithelial cells, …
(IGF)-I and IGF-II, exerts mitogenic effects on normal and malignant breast epithelial cells, …
[HTML][HTML] Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast …
…, B Thürlimann, S Tjulandin, M Toi, M Trudeau… - Annals of oncology, 2021 - Elsevier
The 17th St Gallen International Breast Cancer Consensus Conference in 2021 was held
virtually, owing to the global COVID-19 pandemic. More than 3300 participants took part in this …
virtually, owing to the global COVID-19 pandemic. More than 3300 participants took part in this …
[HTML][HTML] Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer
…, DR McCready, LA Manchul, ME Trudeau… - … England Journal of …, 2004 - Mass Medical Soc
Background We determined the effect of breast irradiation plus tamoxifen on disease-free
survival and local relapse in women 50 years of age or older who had T1 or T2 node-negative …
survival and local relapse in women 50 years of age or older who had T1 or T2 node-negative …
[HTML][HTML] Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with≥ 2 HER2-directed regimens …
…, N Masuda, M Palacova, ME Trudeau… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
METHODS Patients, including those with stable, asymptomatic CNS disease, were randomly
assigned 1: 1 to neratinib (240 mg once every day) plus capecitabine (750 mg/m 2 twice a …
assigned 1: 1 to neratinib (240 mg once every day) plus capecitabine (750 mg/m 2 twice a …
Pattern of metastatic spread in triple-negative breast cancer
R Dent, WM Hanna, M Trudeau, E Rawlinson… - Breast cancer research …, 2009 - Springer
Purpose The prognosis of women with triple-negative breast cancers (defined as cancers that
are estrogen receptor-negative, progesterone receptor-negative and HER2/neu negative) …
are estrogen receptor-negative, progesterone receptor-negative and HER2/neu negative) …
Risk of menopause during the first year after breast cancer diagnosis
…, M Ennis, KI Pritchard, M Trudeau… - Journal of clinical …, 1999 - ascopubs.org
PURPOSE: Premenopausal women with breast cancer often enter a premature menopause
during initial treatment of their malignancy, with resulting loss of childbearing capacity, onset …
during initial treatment of their malignancy, with resulting loss of childbearing capacity, onset …
[HTML][HTML] Enzalutamide for the treatment of androgen receptor–expressing triple-negative breast cancer
…, A Awada, L Garcia-Estevez, ME Trudeau… - Journal of clinical …, 2018 - ncbi.nlm.nih.gov
Purpose Studies suggest that a subset of patients with triple-negative breast cancer (TNBC)
have tumors that express the androgen receptor (AR) and may benefit from an AR inhibitor. …
have tumors that express the androgen receptor (AR) and may benefit from an AR inhibitor. …
Blood-brain barrier opening in primary brain tumors with non-invasive MR-guided focused ultrasound: a clinical safety and feasibility study
The blood-brain barrier (BBB) has long limited therapeutic access to brain tumor and
peritumoral tissue. In animals, MR-guided focused ultrasound (MRgFUS) with intravenously …
peritumoral tissue. In animals, MR-guided focused ultrasound (MRgFUS) with intravenously …
Adjuvant treatment and onset of menopause predict weight gain after breast cancer diagnosis
…, D McCready, J Koo, S Sidlofsky, M Trudeau… - Journal of Clinical …, 1999 - ascopubs.org
PURPOSE: Weight gain is common during the first year after breast cancer diagnosis. In this
study, we examined clinical factors associated with body size at diagnosis and weight gain …
study, we examined clinical factors associated with body size at diagnosis and weight gain …
